Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 1999;99:2402-2407

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newton, G. E.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newton, G. E.
Right arrow Articles by Parker, J. D.
Related Collections
Right arrow Congestive
Right arrow Cardiovascular Pharmacology

(Circulation. 1999;99:2402-2407.)
© 1999 American Heart Association, Inc.

Clinical Investigation and Reports

Inotropic and Sympathetic Responses to the Intracoronary Infusion of a ß2-Receptor Agonist

A Human In Vivo Study

Gary E. Newton, MD; Eduardo R. Azevedo, MD; John D. Parker, MD

From the Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada.

Correspondence to John D. Parker, MD, Cardiovascular Division, Mount Sinai Hospital, 600 University Ave, Suite 1609, Toronto, Ontario M5G 1X5 Canada. E-mail jdp{at}inforamp.net

Background—On the basis of the presence of ß2-receptors within the sympathetic nervous system, ß2-stimulation may increase cardiac sympathetic outflow. We addressed the hypothesis that sympathoexcitatory ß2-receptors are present in the human left ventricle.

Methods and Results—The ß2-agonist salbutamol was infused into the left coronary artery in 3 groups of patients: group 1 (n=9, no ß-blocker therapy), group 2 (n=7, ß1-selective blockade with atenolol), and group 3 (n=6, nonselective ß-blockade with nadolol). Left ventricular +dP/dt in response to increasing concentrations of salbutamol was measured in all groups, and cardiac norepinephrine spillover was measured in group 1. There were no systemic hemodynamic changes in any group. Salbutamol resulted in a 44±6% increase in +dP/dt in group 1, a 25±6% increase in group 2 (P<0.05 versus group 1), and no increase in group 3. Salbutamol also resulted in a 124±37% increase in cardiac norepinephrine spillover in group 1 (P<0.05).

Conclusions—Evidence that salbutamol increased norepinephrine release from cardiac sympathetic nerves was provided by the observations that atenolol suppressed the salbutamol inotropic response, demonstrating that this response was mediated in part by ß1-receptors and that salbutamol also resulted in an increase in cardiac norepinephrine spillover. This result provides in vivo evidence, in humans, for the role of sympathoexcitatory cardiac ß2-receptors.


Key Words: salbutamol • atenolol • nadolol • ventricles • norepinephrine




This article has been cited by other articles:


Home page
 CirculationHome page
N. Sotoodehnia, D. S. Siscovick, M. Vatta, B. M. Psaty, R. P. Tracy, J. A. Towbin, R. N. Lemaitre, T. D. Rea, J. P. Durda, J. M. Chang, et al.
{beta}2-Adrenergic Receptor Genetic Variants and Risk of Sudden Cardiac Death
Circulation, April 18, 2006; 113(15): 1842 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
T. Nieminen, T. Lehtimaki, J. Laiho, R. Rontu, K. Niemela, T. Koobi, R. Lehtinen, J. Viik, V. Turjanmaa, and M. Kahonen
Effects of polymorphisms in beta1-adrenoceptor and {alpha}-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study
J Appl Physiol, February 1, 2006; 100(2): 507 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. Kaye and M. Esler
Sympathetic neuronal regulation of the heart in aging and heart failure
Cardiovasc Res, May 1, 2005; 66(2): 256 - 264.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. G. Burniston, L.-B. Tan, and D. F. Goldspink
{beta}2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle
J Appl Physiol, April 1, 2005; 98(4): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. Barbato, F. Piscione, J. Bartunek, G. Galasso, P. Cirillo, G. De Luca, G. Iaccarino, B. De Bruyne, M. Chiariello, and W. Wijns
Role of {beta}2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries
Circulation, January 25, 2005; 111(3): 288 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. M. Kaye, B. Smirk, S. Finch, C. Williams, and M. D. Esler
Interaction between cardiac sympathetic drive and heart rate in heart failure: Modulation by adrenergic receptor genotype
J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2008 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Foerster, F. Groner, J. Matthes, W. J. Koch, L. Birnbaumer, and S. Herzig
Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through {beta}2-adrenoceptors
PNAS, November 25, 2003; 100(24): 14475 - 14480.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Velez-Roa, M. Renard, J.-P. Degaute, and P. van de Borne
Peripheral sympathetic control during dobutamine infusion: effects of aging and heart failure
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1605 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. H. Au, E. M. Udris, V. S. Fan, J. R. Curtis, M. B. McDonell, and S. D. Fihn
Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled {beta}-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunction
Chest, June 1, 2003; 123(6): 1964 - 1969.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. S. Goldstein, C. Holmes, S. M. Frank, R. Dendi, R. O. Cannon III, Y. Sharabi, M. D. Esler, and G. Eisenhofer
Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes
Circulation, October 29, 2002; 106(18): 2358 - 2365.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Al-Hesayen, E. R. Azevedo, G. E. Newton, and J. D. Parker
The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure
J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1269 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. R. Azevedo, T. Kubo, S. Mak, A. Al-Hesayen, A. Schofield, R. Allan, S. Kelly, G. E. Newton, J. S. Floras, and J. D. Parker
Nonselective Versus Selective {beta}-Adrenergic Receptor Blockade in Congestive Heart Failure: Differential Effects on Sympathetic Activity
Circulation, October 30, 2001; 104(18): 2194 - 2199.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M D Lowe, E Rowland, M J Brown, and A A Grace
{beta}2 Adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium
Heart, July 1, 2001; 86(1): 45 - 51.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. M. Kaye, L. Johnston, G. Vaddadi, H. Brunner-LaRocca, G. L. Jennings, and M. D. Esler
Mechanisms of Carvedilol Action in Human Congestive Heart Failure
Hypertension, May 1, 2001; 37(5): 1216 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. R. Bristow
{beta}-Adrenergic Receptor Blockade in Chronic Heart Failure
Circulation, February 8, 2000; 101(5): 558 - 569.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
O.-E. Brodde and M. C. Michel
Adrenergic and Muscarinic Receptors in the Human Heart
Pharmacol. Rev., December 1, 1999; 51(4): 651 - 690.
[Abstract] [Full Text] [PDF]


Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.